Based in Berkeley, CA, Actym Therapeutics has developed a microbial-based immunotherapeutic technology platform called STACT, which specifically targets solid tumors without affecting healthy tissue. STACT delivers immuno-modulatory payloads directly to immune cells within tumors, addressing limitations of current therapies. In April 2020, Actym raised $34 million in a Series A financing round led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures. The company aims to target intractable immune pathways in the tumor microenvironment and provide better forms of cancer treatment.